David Bargiela1, Matthew T Bianchi1, M Brandon Westover1, Lori B Chibnik1, Brian C Healy1, Philip L De Jager1, Zongqi Xia2. 1. From the Ann Romney Center for Neurologic Diseases (D.B., B.C.H., P.L.D.J., Z.X.), Department of Neurology, and Program in Translational Neuropsychiatric Genomics (D.B., P.L.D.J., Z.X.), Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston; Program for Medical and Population Genetics (D.B., L.B.C., P.L.D.J., Z.X.), Broad Institute, Cambridge; Harvard Medical School (D.B., M.T.B., M.B.W., L.B.C., P.L.D.J., Z.X.); Department of Neurology (M.T.B., M.B.W.) and Biostatistics Center (B.C.H.), Massachusetts General Hospital; Harvard T.H. Chan School of Public Health (L.B.C.), Boston, MA; and Department of Neurology (Z.X.), University of Pittsburgh, PA. 2. From the Ann Romney Center for Neurologic Diseases (D.B., B.C.H., P.L.D.J., Z.X.), Department of Neurology, and Program in Translational Neuropsychiatric Genomics (D.B., P.L.D.J., Z.X.), Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston; Program for Medical and Population Genetics (D.B., L.B.C., P.L.D.J., Z.X.), Broad Institute, Cambridge; Harvard Medical School (D.B., M.T.B., M.B.W., L.B.C., P.L.D.J., Z.X.); Department of Neurology (M.T.B., M.B.W.) and Biostatistics Center (B.C.H.), Massachusetts General Hospital; Harvard T.H. Chan School of Public Health (L.B.C.), Boston, MA; and Department of Neurology (Z.X.), University of Pittsburgh, PA. zxia1@pitt.edu.
Abstract
OBJECTIVE: To integrate long-term measures of disease-modifying drug efficacy and risk to guide selection of first-line treatment of multiple sclerosis. METHODS: We created a Markov decision model to evaluate disability worsening and progressive multifocal leukoencephalopathy (PML) risk in patients receiving natalizumab (NTZ), fingolimod (FGL), or glatiramer acetate (GA) over 30 years. Leveraging publicly available data, we integrated treatment utility, disability worsening, and risk of PML into quality-adjusted life-years (QALYs). We performed sensitivity analyses varying PML risk, mortality and morbidity, and relative risk of disease worsening across clinically relevant ranges. RESULTS: Over the entire reported range of NTZ-associated PML risk, NTZ as first-line therapy is predicted to provide a greater net benefit (15.06 QALYs) than FGL (13.99 QALYs) or GA (12.71 QALYs) treatment over 30 years, after accounting for loss of QALYs due to PML or death (resulting from all causes). NTZ treatment is associated with delayed worsening to an Expanded Disability Status Scale score ≥6.0 vs FGL or GA (22.7, 17.0, and 12.4 years, respectively). Compared to untreated patients, NTZ-treated patients have a greater relative risk of death in the early years of treatment that varies according to PML risk profile. CONCLUSIONS: NTZ as a first-line treatment is associated with the highest net benefit across full ranges of PML risk, mortality, and morbidity compared to FGL or GA. Integrated modeling of long-term treatment risks and benefits informs stratified clinical decision-making and can support patient counseling on selection of first-line treatment options.
OBJECTIVE: To integrate long-term measures of disease-modifying drug efficacy and risk to guide selection of first-line treatment of multiple sclerosis. METHODS: We created a Markov decision model to evaluate disability worsening and progressive multifocal leukoencephalopathy (PML) risk in patients receiving natalizumab (NTZ), fingolimod (FGL), or glatiramer acetate (GA) over 30 years. Leveraging publicly available data, we integrated treatment utility, disability worsening, and risk of PML into quality-adjusted life-years (QALYs). We performed sensitivity analyses varying PML risk, mortality and morbidity, and relative risk of disease worsening across clinically relevant ranges. RESULTS: Over the entire reported range of NTZ-associated PML risk, NTZ as first-line therapy is predicted to provide a greater net benefit (15.06 QALYs) than FGL (13.99 QALYs) or GA (12.71 QALYs) treatment over 30 years, after accounting for loss of QALYs due to PML or death (resulting from all causes). NTZ treatment is associated with delayed worsening to an Expanded Disability Status Scale score ≥6.0 vs FGL or GA (22.7, 17.0, and 12.4 years, respectively). Compared to untreated patients, NTZ-treated patients have a greater relative risk of death in the early years of treatment that varies according to PML risk profile. CONCLUSIONS:NTZ as a first-line treatment is associated with the highest net benefit across full ranges of PML risk, mortality, and morbidity compared to FGL or GA. Integrated modeling of long-term treatment risks and benefits informs stratified clinical decision-making and can support patient counseling on selection of first-line treatment options.
Authors: Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin Journal: Lancet Neurol Date: 2014-03-28 Impact factor: 44.182
Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Jonathan D Campbell; R Brett McQueen; Agusto Miravalle; John R Corboy; Timothy L Vollmer; Kavita Nair Journal: Am J Manag Care Date: 2013-04 Impact factor: 2.229
Authors: Jacqueline Palace; Thomas Bregenzer; Helen Tremlett; Joel Oger; Feng Zhu; Fheng Zhu; Mike Boggild; Martin Duddy; Charles Dobson Journal: BMJ Open Date: 2014-01-17 Impact factor: 2.692
Authors: Tracey J Weiland; George A Jelinek; Claudia H Marck; Emily J Hadgkiss; Dania M van der Meer; Naresh G Pereira; Keryn L Taylor Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: André Eduardo de Almeida Franzoi; Fernanda Subtil de Moraes Machado; Washigton Luiz Gomes de Medeiros Junior; Isabelle Pastor Bandeira; Wesley Nogueira Brandão; Marcus Vinicius Magno Gonçalves Journal: Heliyon Date: 2021-06-09